A Lymphoma Growth Inhibitor Blocks Some but Not All Prolactin-stimulated Signaling Pathways*

Hiroko YamashitaDagger , Jun XuDagger , Rebecca A. Erwin§, Andrew C. Larner, and Hallgeir RuiDagger parallel

From the Dagger  Department of Pathology, Uniformed Services University of the Health Sciences School of Medicine, Bethesda, Maryland 20814, § Department of Integrative Biology, Pharmacology and Physiology, University of Texas, Houston, Texas 77030, and  Department of Immunology, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, Ohio 44195

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cytokines and hormones activate a network of intracellular signaling pathways to regulate cell division, survival and differentiation. In parallel, a series of growth inhibitory mechanisms critically restrict cell population sizes. For example, mitogens can be opposed in crowded cell cultures through contact-inhibition or by autocrine release of antiproliferative substances. Here, we characterize a small, heat-stable growth inhibitor secreted by a rat T lymphoma line when cultured at high cell density. Short term incubation (<60 min) of prolactin-responsive Nb2 lymphoma cells at high density selectively blocked prolactin stimulation of p42/p44 mitogen-activated protein kinases and transcription factors Stat1 and Stat3 but not prolactin activation of Stat5 or the tyrosine kinase Jak2. The selective effects of cell density on prolactin signaling were reversible. Furthermore, exposure of cells at low density to conditioned media from cells incubated at high density had the same inhibitory effects on prolactin signaling. This selective inhibition of discrete prolactin signals was mimicked by short term preincubation of cells at low density with staurosporine or genistein but not with bis-indoleyl maleimide, cyclic nucleotide analogs, calcium ionophore A23187, or phorbol 12-myristate 13-acetate. A heat-stable, proteinase K-resistant, low molecular weight factor with these characteristics was recovered from high density culture medium. The partially purified inhibitor suppressed Nb2 cell growth with a sigmoidal concentration response consistent with a saturable, receptor-mediated process.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell proliferation, differentiation, and death are controlled in a coordinated manner by soluble factors, extracellular matrix proteins, and direct cell-cell contact (1, 2). These extracellular regulators influence a series of positive and negative intracellular signaling pathways that translate into a net cellular response. Several mechanisms for growth suppression coexist in normal cells. Direct cell-cell contact inhibition and growth suppression through local secretion of inhibitors work to limit proliferation (3). Although some of these physiological mechanisms may become dysfunctional and thus contribute to malignant transformation and tumor progression, many remain operative in transformed cells. For example, loss of sensitivity to transforming growth factor-beta , an autocrine growth inhibitor, is frequently observed in malignant cells (4), whereas contact-inhibition or cell density-induced growth inhibition may remain intact (5, 6). During studies of prolactin(PRL)1-induced signal transduction in rat Nb2 lymphoma cells, we observed that cell crowding selectively inhibited some but not all PRL-inducible signals, suggesting the existence of a cell density-dependent mechanism for modulation of discrete PRL signals.

Nb2 lymphoma cells are of early T cell lineage and originated in the lymph node of an estrogenized male rat (7). These cells represent a widely used model for PRL-induced signal transduction and gene regulation (8-10). Despite expressing a mutant PRL receptor that lacks an internal portion of the cytoplasmic domain (11), Nb2 cells respond to PRL by activating multiple signaling pathways. Stimulation of the receptor-associated tyrosine kinase Jak2 (12, 13) is followed by activation of several signaling proteins, including latent cytoplasmic transcription factors Stat1, Stat3, Stat5a, and Stat5b (14-17), and the Shc-Ras-Raf mitogen-activated protein kinase (MAPK) pathway (18-20). In addition, the Src-tyrosine kinase Fyn (21), the phosphatidylinositol-3 kinase pathway (22), and protein kinase C (23) have also been reported to be activated by PRL in Nb2 cells.

We now demonstrate that short term incubation of Nb2 cells at high cell density selectively blocked PRL stimulation of p42/p44 MAPK and transcription factors Stat1 and Stat3 but did not affect PRL activation of Stat5 or Jak2 tyrosine kinase. This response to cell crowding was reversible and was mimicked at low cell density by short term exposure to conditioned high density medium, staurosporine or genistein. A low molecular weight, heat-stable, and proteinase K-resistant factor with these characteristics was recovered from conditioned high density medium. Of particular importance, the partially purified factor also inhibited cell growth in a saturable dose-dependent fashion, suggesting operation through a receptor-mediated mechanism.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Ovine PRL (NIDDK-oPRL-19, AFP-9221A) was supplied by the National Hormone and Pituitary Program, NIDDK, the NICHD, and the U.S. Department of Agriculture. Polyclonal rabbit antisera specific to peptides corresponding to the unique COOH termini of Stat1alpha , Stat3, Stat5a, and Stat5b were generated as described previously (17, 24). In addition, a polyclonal rabbit antiserum that recognized both the 92-94-kDa alpha -forms and the COOH-terminally truncated 82-84-kDa beta -forms of Stat5a/b was raised against a peptide derived from the originally published sequence of sheep Stat5a as described previously (17). Each antiserum was useful for detection of rat Stat proteins by immunoprecipitation and immunoblotting. Monoclonal anti-phosphotyrosine antibody 4G10 and polyclonal rabbit antiserum to Jak2 were purchased from Upstate Biotechnology (catalog numbers 05-321 and 06-255, respectively). Affinity-purified rabbit antibodies to active MAPK were purchased from Promega (catalog number V667A).

Cell Culture and Treatment-- The Nb2 cell line (7) was originally developed by Dr. Peter Gout (Vancouver, Canada), the Nb2-SP clone used in this study was generously provided by Dr. Henry Friesen (Manitoba, Canada). Cells were grown in RPMI 1640 medium (Mediatech, catalog number 15-040-LM) containing 10% fetal calf serum (Intergen, catalog number 1020-90), 2 mM L-glutamine, 5 mM HEPES, pH 7.3, and penicillin-streptomycin (50 IU/ml and 50 µg/ml, respectively), at 37 °C with 5% CO2. Before use in PRL stimulation experiments, Nb2 cells at a density of 1-1.5 × 106/ml were incubated for 20-24 h in PRL/lactogen-free medium consisting of RPMI 1640, which instead of 10% fetal calf serum contained 1% gelded horse serum (Sigma, catalog number H-1895), hereafter referred to as starvation medium. At the beginning of each experiment, cells were concentrated to the desired density and incubated for the various periods as indicated in the presence or absence of 100 nM ovine PRL during the final 15 min. Cell pellets were frozen at -70 °C.

Solubilization of Proteins, Immunoprecipitation, and Immunoblotting-- Frozen pellets from 1 × 108 Nb2 cells were thawed on ice and solubilized in 1 ml of lysis buffer containing 10 mM Tris-HCl, pH 7.6, 5 mM EDTA, 50 mM NaCl, 30 mM sodium pyrophosphate, 50 mM sodium fluoride, 1 mM sodium orthovanadate, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 5 µg/ml aprotinin, 1 µg/ml pepstatin A, and 2 µg/ml leupeptin. Cell lysates were rotated end over end at 4 °C for 60 min, and insoluble material was pelleted at 12,000 × g for 30 min at 4 °C. Depending on the experiment, clarified lysates were incubated rotating end over end for 3 h at 4 °C with polyclonal rabbit antisera (3 µl/ml) to individual Jak2 and Stat proteins as specified. Antibodies were captured by incubation for 60 min with protein A-Sepharose beads (Amersham Pharmacia Biotech, catalog number 17-0780-01), and proteins were analyzed by SDS-polyacrylamide gel electrophoresis and immunoblotting as described previously (17), using polyvinylidene difluoride membranes (Millipore, catalog number 1PVH 00010) and horseradish-conjugated secondary antibodies in conjunction with enhanced chemiluminescence substrate mixture (Amersham Pharmacia Biotech, catalog number RPN2106) and x-ray film.

Preparation of Conditioned High Density Medium (HDM)-- Nb2 cells that had been cultured in PRL-free starvation medium for 20-24 h at a density of 1-1.5 × 106 cells/ml were brought to a high cell density of 4.0 × 108 cells/ml and incubated for 1 h in the same culture medium at 37 °C. The cells were discarded after centrifugation at 3,000 × g for 5 min at 4 °C, and the conditioned medium was passed through a 0.22-µm filter and used fresh unless indicated otherwise. For some experiments, conditioned HDM was boiled for 10 min, followed by incubation on ice for 30 min with subsequent clarification by centrifugation at 12,000 × g for 30 min at 4 °C to remove precipitated proteins. For dialysis experiments, dialysis membranes with a molecular weight cutoff of 10 kDa (Schleicher & Schuell, catalog number 25310) were used, and the dialysis medium was either 100 volumes of starvation medium for removal of low molecular weight material or four volumes of water for recovery of the low molecular weight fraction.

Cell Proliferation Assays-- Nb2 cells were dispensed into 96-well microtiter plates at 1 × 105 cells/100 µl and exposed for 48 h to either control medium or conditioned HDM in some experiments or in dose-response experiments to various dilutions of the reconstituted low molecular weight material derived from boiled and clarified HDM. The number of viable cells were measured metabolically by the Promega cell proliferation assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) as described previously (25). Colorimetric analysis was performed using a semiautomatic plate reader from Dynatech Laboratories (MR 600) at absorbance 590 nm.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Selective Inhibition at High Cell Density of PRL-inducible Activation of Stat1, Stat3, and ERK1/2 but not Jak2 and Stat5-- To examine the effect of cell crowding on PRL-induced signal transduction, Nb2 cells were incubated at increasing concentrations (range 0.25-4.0 × 108 cells/ml) for 45 min, with or without prolactin (100 nM) added during the final 15 min. Cells were maintained in suspension by manual agitation every 5 min during the entire incubation period. PRL-inducible tyrosine phosphorylation of Jak2, Stat1, Stat3, and Stat5 was subsequently analyzed by immunoblotting of immunoprecipitated proteins from detergent cell lysates. Parallel samples of whole cell lysates were also immunoblotted with anti-phospho-MAPK antibodies to detect activated ERK1 and ERK2. Immunoblotting with anti-phosphotyrosine antibodies or anti-phospho-specific MAPK antibodies showed that PRL-inducible activation of Stat1, Stat3, and ERK1/2 was significantly inhibited by increasing cell density, particularly at 2-4 × 108 cells/ml (Fig. 1, lanes g-j, panels 3, 5, and 7 as numbered from the top). In contrast, PRL-inducible tyrosine phosphorylation of Jak2 and Stat5 remained unaffected by cell density (Fig. 1, lanes a and b versus i and j, panels 1 and 9). In parallel, basal levels of ERK1/2 activation were also significantly suppressed under high cell density conditions (Fig. 1). Reblotting of the same or duplicate samples for protein levels did not reveal any systematic changes in protein levels during the 45-min experiment period that could explain the marked reductions in signals by either Stat1, Stat3, or MAPK.


View larger version (79K):
[in this window]
[in a new window]
 
Fig. 1.   Selective inhibition at high cell density of PRL-inducible phosphorylation of Stat1, Stat3, and ERK1/2 but not Jak2 and Stat5. Nb2 cells were incubated at 37 °C for a total of 45 min at various cell densities before stimulation with (+) or without (-) 100 nM of ovine PRL during the final 15 min. Clarified cell lysates were immunoprecipitated with antibodies to Jak2, Stat1alpha , Stat3, and Stat5 and subsequently blotted with anti-phosphotyrosine antibodies (alpha -PY). Parallel samples representing whole cell lysates were also immunoblotted with anti-phospho-MAPK antibodies (alpha -pMAPK) to detect activated ERK1 and ERK2. In addition, reblotting of the same or parallel samples for protein levels were performed as indicated.

Previously, we had established by electrophoretic mobility shift assays that PRL-activated Stat5 and Stat1 from Nb2 cells form distinguishable complexes with an oligonucleotide probe derived from the rat beta -casein promoter, whereas PRL-activated Stat3 does not bind to this DNA sequence (17, 26, 27). Parallel electrophoretic mobility shift analyses of Stat1 and Stat5 binding to this beta -casein promoter probe showed a corresponding selective inhibition by cell crowding of PRL-inducible Stat1 activation.2

The Selective Inhibition at High Cell Density of PRL Activation of Stat1, Stat3, and ERK1/2 Is Rapid and Reversible-- Having demonstrated that a selective uncoupling of certain PRL-induced signals occurred at high cell density, we examined how rapidly this inhibition of PRL-inducible Stat1 and Stat3 tyrosine phosphorylation occurred, and whether the inhibitory effect could be reversed by dilution of the cells. Incubation of cells at high density (4.0 × 108 cells/ml) for varying times up to 75 min, with or without PRL added during the final 15 min of each period, showed that whereas PRL-inducible Jak2 tyrosine phosphorylation was unaffected by cell crowding over the entire period, PRL-inducible tyrosine phosphorylation of both Stat1 and Stat3 was significantly inhibited after 30 min and completely after 75 min (Fig. 2A).


View larger version (52K):
[in this window]
[in a new window]
 
Fig. 2.   The selective inhibition at high cell density of PRL activation of Stat1, Stat3, and ERK1/2 is rapid and reversible. A, parallel samples of Nb2 cells were incubated at low density (0.5 × 108 cells/ml) and/or high density (4 × 108 cells/ml) for a combined period of 75 min at 37 °C with (+) or without (-) 100 nM ovine PRL added during the final 15 min. At variable times before the end of the 75-min incubation period, cells were switched from low density (0.5 × 108 cells/ml) to high density (4 × 108 cells/ml) by centrifugation and volume reduction, so that the individual cell samples were crowded for periods ranging from 0 to 75 min as indicated. Clarified cell lysates were immunoprecipitated (IP) with antibodies to Jak2, Stat1alpha , or Stat3, then blotted with anti-phosphotyrosine antibodies (alpha -PY). B, Nb2 cells were incubated at 37 °C for 30 min at low cell density (0.5 × 108 cells/ml; lanes a and b) or high cell density (4.0 × 108 cells/ml; lanes c-f) before stimulation with (+) or without (-) 100 nM of ovine PRL for 15 min at low cell density (lanes a, b, e, and f) or high cell density (lanes c and d). Clarified cell lysates were immunoprecipitated with antibodies to Jak2, Stat1alpha , Stat3, or Stat5, then blotted with anti-phosphotyrosine antibodies (alpha -PY). Parallel samples of whole cell lysates were also immunoblotted with alpha -pMAPK antibodies.

We also investigated whether this inhibition of discrete PRL signals was reversible upon dilution of cells. Nb2 cells were preincubated at high density (4.0 × 108 cells/ml) for 30 min, followed by either continued incubation at high cell density or dilution to low cell density (0.5 × 108 cells/ml) for 15 min in the presence or absence of PRL. Parallel control cells were also incubated at low cell density for the entire 45-min period with or without PRL during the final 15 min (Fig. 2B, lanes a and b). PRL-inducible tyrosine phosphorylation of Stat1 and Stat3 and ERK1/2 activation, but not Jak2 and Stat5 tyrosine phosphorylation, was significantly inhibited as observed previously when incubated at high density for 45 min (Fig. 2B, panels 1-5, lanes a-d). However, this selective inhibition of PRL-inducible Stat1, Stat3, and ERK1/2 phosphorylation was completely reversed by dilution for 15 min to low density after preincubation for 30 min at high cell density (Fig. 2B, panels 2-4, lanes e and f). Reblotting of samples for protein expression levels were consistent with the previous data shown in Fig. 1, demonstrating that density-induced inhibition of Stat1, Stat3, and ERK1/2 signals could not be explained by systematic reductions in protein levels (data not shown). Based on these experiments, we conclude that the inhibitory effect of cell crowding on discrete PRL signals was rapid and reversible. Because of the rapid reversal of signal suppression upon dilution to low cell density, and the short time at high cell density needed for establishing the inhibitory effect, we favored a direct mechanism that exclusively involved cell-cell contact. However, it remained possible that the effect of cell crowding also included the release of a soluble suppressor substance.

A Low Molecular Weight Factor in Conditioned High Density Medium Selectively Modulates PRL Signals-- To directly test whether a soluble mediator could account for the observed effects, we analyzed the effect of conditioned HDM on PRL signals in cells incubated at low density (0.5 × 108 cells/ml). HDM was generated by incubating parallel cultures of Nb2 cells at high density (4.0 × 108 cells/ml) for 60 min at 37 °C followed by removal of cells by centrifugation. Contrary to our expectation, short term incubation of cells at low cell density in freshly generated HDM also led to selective suppression of PRL-inducible tyrosine phosphorylation of Stat1 and not of PRL-inducible Jak2 activation (Fig. 3A, lanes a-f). These observations suggested that a soluble factor was indeed present in freshly generated HDM that could mediate the suppression caused by cell crowding and showed that increased cell-cell contact per se was not required to achieve the inhibitory effect. Furthermore, these experiments showed that the soluble inhibitory activity was stable, because the activity persisted in HDM that had been stored for 24 h at 4 °C (Fig. 3A, lanes g and h) and in HDM that had been boiled for 10 min followed by centrifugation at 12,000 × g for 30 min (Fig. 3A, lanes i and j). On the other hand, the soluble inhibitory activity was lost upon dialysis of boiled and clarified HDM against 100 volumes of starvation medium at 4 °C for 12 h using a molecular weight cutoff of 10 kDa (Fig. 3A, lanes k and l). Collectively, these results indicated that a heat-stable low molecular weight factor present in HDM could mediate the inhibition of discrete PRL signals induced by cell crowding.


View larger version (45K):
[in this window]
[in a new window]
 
Fig. 3.   A low molecular weight factor from high density medium selectively modulates PRL signals. A, effect of conditioned high density medium on PRL signals. Quiescent Nb2 cells were incubated at 37 °C for a total of 45 min in the presence (+) or absence (-) of 100 nM ovine PRL during the final 15 min at either low cell density (0.5 × 108 cells/ml; lanes a and b) or high cell density (4 × 108 cells/ml; lanes c and d) in control medium (Ctrl), or at low cell density in conditioned HDM that had been either freshly generated (Fresh; lanes e and f), stored at 4 °C for 24 h (Old; lanes g and h), boiled for 10 min and clarified (12,000 × g for 30 min; Boiled; lanes i and j), or boiled, clarified and dialyzed using a molecular weight cutoff of 10 kDa against 100 volumes of starvation medium (Dialyzed; lanes k and l). Cell lysates were immunoprecipitated (IP) with antibodies to Jak2 or Stat1alpha , and blotted with anti-phosphotyrosine antibodies (alpha -PY). B, effect of low molecular weight fraction from boiled conditioned high density medium on PRL signals. Quiescent Nb2 cells were incubated at 37 °C for a total of 45 min in the presence (+) or absence (-) of 100 nM ovine PRL during the final 15 min at low cell density (lanes a and b) or high cell density (lanes c and d) in control medium (Ctrl), or at low cell density in medium reconstituted with the low molecular weight fraction (<10 kDa) from conditioned high density medium (Low MW; lanes e and f) or the corresponding low molecular weight fraction from control medium (Ctrl Low MW; lanes g and h). Cell lysates were immunoprecipitated with antibodies to Jak2 or Stat1alpha and blotted with anti-phosphotyrosine antibodies (alpha -PY). Parallel samples of whole cell lysates were also immunoblotted with alpha -pMAPK antibodies to detect activated ERK1 and ERK2. C, the low molecular weight factor is insensitive to proteinase K. Control medium (Ctrl) and conditioned HDM were boiled for 10 min, clarified (12,000 × g for 30 min at 4 °C), and treated with (+) or without (-) proteinase K (50 µg/ml) at 37 °C for 1 h, reboiled for 5 min, and reclarified by centrifugation at 12,000 × g for 30 min at 4 °C. The resulting four supernatants then served as incubation medium to examine the sensitivity of the low molecular weight factor to proteinase K. Nb2 cells were incubated at 37 °C for a total of 45 min in the presence (+) or absence (-) of 100 nM ovine PRL during the final 15 min in media representing either control or conditioned HDM that had been treated with (+) or without (-) proteinase K as indicated. Clarified cell lysates were immunoprecipitated (IP) with antibodies to Jak2 or Stat1alpha , followed by blotting with anti-phosphotyrosine antibodies (alpha -PY). D, proteinase K is enzymatically active under the conditions used. Condi tioned low-density medium was spiked with prolactin (10 nM) and incubated for 30 min at 37 °C in the presence or absence of proteinase K before cells were added for a 5-min stimulation period and Jak2 tyrosine phosphorylation was assayed.

We then tested whether this small heat-stable factor could be recovered from the dialysis medium. Conditioned HDM was boiled, clarified, and dialyzed against 4 volumes of water overnight at 4 °C using a molecular weight cutoff of 10 kDa. The dialysate was discarded, and the resulting dialysis fluid containing low molecular weight material was lyophilized and restored with water to a stock concentration corresponding to 10 × HDM. This concentrated low molecular weight fraction of HDM was diluted 1:10 in cell culture medium and specifically tested for its ability to affect PRL activation of Jak2, Stat1, and ERK1/2. In control samples, incubation at high cell density was associated with inhibition of PRL-inducible Stat1 and ERK1/2 but not Jak2 signals (Fig. 3B, lanes a-d). Likewise, cells incubated at low cell density in medium containing the reconstituted low molecular weight fraction of HDM also showed selective inhibition of PRL-inducible phosphorylation of Stat1 and ERK1/2 without affecting Jak2 phosphorylation (Fig. 3B, lanes e and f). In addition, this reconstituted dialysis medium inhibited basal activity of ERK1/2 (Fig. 3B, panel 3, lane e), thus also mimicking this particular effect of cell crowding. On the other hand, no inhibition was seen in cells incubated in control medium containing the low molecular weight fraction from low density starvation medium, which had also been boiled, clarified, dialyzed, and reconstituted correspondingly (Fig. 3B, lanes g and h). We conclude that a small heat-stable activity that specifically mimicked the effect of cell crowding could be recovered by dialysis of HDM that had been boiled and clarified.

To address whether the inhibitory factor present in boiled and clarified HDM was a peptide, we tested its sensitivity to proteinase K, a general endoprotease that cleaves nonselectively after any hydrophobic, aliphatic, or aromatic amino acid (28). For these experiments, boiled and clarified HDM or corresponding control medium (pH 7.3) were incubated with proteinase K (50 µg/ml) for 1 h at 37 °C, followed by reboiling for 10 min to inactivate the enzyme. Consistent with the previous data, preincubation of cells with boiled and clarified HDM suppressed the PRL-inducible Stat1 signal (Fig. 3C, lanes e and f) when compared with pretreatment with control medium from low density cultures that had been boiled only, or boiled and treated with proteinase K (Fig. 3C, lanes a-d). However, treatment of boiled and clarified HDM with proteinase K did not neutralize the endogenous inhibitor (Fig. 3C, lanes g and h). As a positive control to verify that the proteinase K used was enzymatically active in this biochemical setting, conditioned low density medium was spiked with prolactin (10 nM) and incubated for 30 min at 37 °C in the presence or absence of proteinase K. As shown in Fig. 3D, PRL-induced tyrosine phosphorylation of Jak2 was abolished after proteinase K treatment (lane c versus lane d). Because proteinase K cleaves peptide bonds after more than half of the natural amino acids (28), these observations suggested that the low molecular weight factor may not be a peptide. However, further physicochemical analysis and purification is needed to determine the structure of this factor.

Modulation of Discrete PRL Signals in Nb2 Cells at High Cell Density Is Mimicked by Protein Kinase Inhibitors Staurosporine and Genistein-- We addressed the potential mechanism of action of the high cell density-associated inhibitor by screening a series of pharmacological agents for modulatory effects on PRL-inducible Jak2, Stat1, and Stat3 signals in Nb2 cells. Cells were maintained at low density and were preincubated with pharmacologically active concentrations of each agent for 30 min before PRL was added for another 15 min. The results of these studies are presented in Fig. 4, A and B, and showed that the broad spectrum protein kinase inhibitor, staurosporine (500 nM), specifically mimicked the effect of cell crowding by inhibiting PRL-induced tyrosine phosphorylation of Stat1 and Stat3, while having little or no effect on Jak2 activation (Fig. 4B). In contrast, the more specific protein kinase C (PKC) inhibitor, bis-indolelyl-maleimide (500 µM), did not affect PRL signals, suggesting that the effect of staurosporine is not mediated by inhibition of PKC. On the other hand, genistein (200 µM), a tyrosine kinase inhibitor, also inhibited PRL-induced Stat1 and Stat3, albeit not as markedly as staurosporine (Fig. 4B). No effect was observed after pretreatment with any of the other agents, which included the calcium ionophore A23187 (1 µM), 8-Br-cAMP (1 mM), 8-Br-cGMP (1 mM), the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (100 µM), and the protein kinase C activator phorbol 12-myristate 13-acetate (1 µM). Furthermore, the mimicry of cell crowding by staurosporine and genistein also included resistance of PRL-inducible tyrosine phosphorylation of Stat5a and Stat5b (Fig. 4C), as well as sensitivity of basal and PRL-inducible ERK1/2 activation as recently reported by us and others (29, 30). Thus, staurosporine and to some extent genistein mimicked cell crowding modulation of PRL signals, whereas a series of other agents had no effect. It is therefore possible that the soluble inhibitor acts by a mechanism shared by staurosporine and genistein to regulate PRL signals. Because staurosporine inhibits Nb2 cell growth and survival (26, 30), we tested whether the factor released during cell crowding also inhibited growth of Nb2 lymphoma cells.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 4.   Modulation of discrete PRL signals in Nb2 cells at high cell density is mimicked by staurosporine, a potent protein kinase inhibitor. A, effect of calcium ionophore or cyclic nucleotide mimetics on PRL signals. Nb2 cells were incubated at 37 °C for a total of 45 min with control medium alone (Ctrl), A23187 (1 µM), 8-Br-cAMP (1 mM), 8-Br-cGMP (1 mM), or isobutylmethylxanthine (MIX; 100 µM) in the presence (+) or absence (-) of 100 nM ovine PRL during the final 15 min. Cell lysates were immunoprecipitated (IP) with antibodies to Jak2, Stat1alpha , or Stat3, and blotted with anti-phosphotyrosine antibodies (alpha -PY). B, effect of protein kinase modulators on PRL signals. Nb2 cells were incubated at 37 °C for a total of 45 min with control medium alone (Ctrl), phorbol 12-myristate 13-acetate (PMA; 1 µM), staurosporine (Stsp; 500 nM), bis-indolelylmaleimide (BIM; 500 µM), or genistein (Gstn; 200 µM) in the presence (+) or absence (-) of 100 nM ovine PRL during the final 15 min. Cell lysates were immunoprecipitated (IP) with antibodies to Jak2, Stat1alpha , or Stat3, and blotted with anti-phosphotyrosine antibodies (alpha -PY). C, effect of staurosporine or genistein on PRL-induced Stat5 signals. Quiescent Nb2 cells were incubated at 37 °C with staurosporine (Stsp; 500 nM) or genistein (Gstn; 200 µM) for a total of 45 min with (+) or without (-) 100 nM ovine PRL during the final 15 min. Cell lysates were immunoprecipitated (IP) with antibodies to Jak2, Stat1alpha , Stat3, Stat5a, or Stat5b, and blotted with anti-phosphotyrosine antibodies (alpha -PY).

The Low Molecular Weight Factor in Conditioned High Density Medium Inhibits Nb2 Cell Growth-- We first determined whether complete conditioned HDM inhibited the growth of Nb2 cells. Nb2 cells were cultured at a density of 106 cells/ml in control medium or in conditioned HDM for 48 h. At that point, the number of metabolically active and viable cells were assessed using the MTT cell proliferation assay (25). Under these conditions, HDM significantly inhibited cell growth by approximately 60-65% (n = 3; p < 0.0001; Fig. 5A). Based on these observations, we specifically tested the partially purified factor obtained after dialysis of boiled HDM for its growth inhibitory activity. It was of particular importance to establish whether this partially purified activity exerted a saturable concentration-dependent effect and was not simply cytotoxic. For these experiments, three independently obtained stock solutions containing the partially purified factor at a concentration corresponding to 10× HDM were tested separately. The solutions were diluted in culture medium to achieve concentrations corresponding to a range of 0.25-2× HDM. Nb2 cells were then incubated for 48 h with increasing concentrations of the reconstituted low molecular weight material derived from either conditioned HDM or from low density control medium, and cell growth rate was assayed by the MTT method. As shown in Fig. 5B, the inhibitory effect of the soluble extract displayed a sigmoidal growth inhibition curve reaching a plateau at approximately 65%. These observations therefore strongly suggested that the inhibitory activity released during cell crowding operated through a saturable process.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 5.   A low molecular weight factor from high density medium inhibits cell growth. A, effect of conditioned high density medium on cell growth. Nb2 cells were cultured in control medium (Ctrl) or in conditioned HDM at 37 °C for 48 h, and cell numbers were assessed by the MTT assay. MTT formation is expressed as absorbance (OD) at 590 nm. Error bars indicate the mean ± S.E. (n = 3). Differences between groups were compared by Student's t test (***, p < 0.0001). B, concentration-dependent growth inhibition by partially purified low molecular weight factor derived from boiled clarified conditioned high density medium. Nb2 cells were cultured for 48 h in the presence of increasing concentrations of the partially purified factor derived from the low molecular weight fraction after dialysis of boiled and clarified conditioned HDM. The concentration of the partially purified inhibitory factor is presented as units relative to its concentration in conditioned HDM, i.e. the unit 1.00 represents 1× HDM. Cell numbers were assayed by the MTT method, and the data are presented as percent growth inhibition relative to cells treated with corresponding fractions derived from dialysis of boiled and clarified control culture medium. Error bars indicate the mean ± S.E. (n = 3).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

This study describes a small heat-stable growth inhibitor secreted by a rat T lymphoma line when cultured at high cell density. The data also suggested that this inhibitor selectively and reversibly suppressed some, but not all, signaling pathways downstream of PRL receptors. Specifically, short term incubation of Nb2 lymphoma cells at high density blocked PRL stimulation of mitogen-activated protein kinases ERK1/2 and transcription factors Stat1 and Stat3 but did not affect PRL activation of Stat5 or the tyrosine kinase Jak2. These effects of cell crowding were reversible and could be imitated by incubation of cells in conditioned high density culture medium at low cell density. A heat-stable and proteinase K-resistant low molecular weight factor (<10 kDa) with these characteristics was recovered from the conditioned high density medium. This factor suppressed basal and PRL-induced MAPK activation and inhibited cell growth with a sigmoidal concentration response consistent with a saturable mode of action.

Common Mechanism of Discrete Signal Modulation by Cell Crowding, Staurosporine and Genistein?-- The discriminating suppression of PRL signals by the growth inhibitor present in conditioned high density medium could under low density culture conditions be specifically mimicked by the broad spectrum protein kinase inhibitor, staurosporine. Short term (30 min) pretreatment of cells with staurosporine was associated with selective inhibition of PRL-inducible Stat1, Stat3, and ERK1/2 signals, with little or no effect on PRL-inducible Stat5 and Jak2 signals. A lesser but similar selective inhibition of PRL signals was induced by the more specific tyrosine kinase inhibitor, genistein. In contrast, PRL signals were not modulated by pretreatment of cells with the PKC inhibitor bis-indoleylmaleimide, the PKC activator phorbol 12-myristate 13-acetate, the calcium ionophore A23187, or several cyclic nucleotide mimetics. Collectively, these pharmacological data raise the possibility that cell crowding, staurosporine, and possibly genistein modulate PRL signals through a common and PKC-independent mechanism. One simple model would involve inhibition by staurosporine, genistein, and cell crowding of a tyrosine kinase that acts downstream of Jak2 and is required for PRL-inducible activation of Stat1, Stat3, and MAPK. Such a role may be played by one or more Src tyrosine kinases. Both staurosporine and genistein inhibit tyrosine kinases of the Src family (30, 31), and Fyn and possibly Lck is activated by PRL in Nb2 cells (21). In parallel studies of Shc, an adaptor protein that we have shown to couple PRL-receptors to the Grb2-Sos-Ras-MAPK pathway in Nb2 cells (19), supported this notion. PRL-inducible tyrosine phosphorylation of Shc was also inhibited after pretreatment with high cell density, staurosporine, or genistein.3 We are currently testing the possibility that Fyn or other Src tyrosine kinases represent common targets for cell crowding, genistein, and staurosporine in Nb2 cells.

A tyrosine kinase acting downstream of Jak2 might critically mediate PRL-induced activation of Stat1/3 and the Shc-Ras-MAPK pathway by two alternative mechanisms. On the one hand, Stat1, Stat3, and Shc could be direct substrates for a density-regulated tyrosine kinase. Alternatively, this putative kinase could phosphorylate tyrosyl docking sites within the receptor complex that are critical for bringing Stat1/3 and/or Shc within reach of the catalytic domain of the Jak2 kinase. Future examination of the sensitivity of specific phosphorylation sites within the prolactin receptor to inhibition by high cell density, staurosporine, and genistein may therefore be highly informative.

Another question that we have addressed is whether density-associated inhibition of MAPK in Nb2 cells may selectively suppress tyrosine phosphorylation of Stat1 and Stat3 but not Stat5. We recently demonstrated that the MEK-1 inhibitor, PD98059, blocked prolactin-induced MAPK activation in Nb2 lymphocytes without affecting inducible Stat5a and Stat5b tyrosine phosphorylation (29). However, further investigation showed that PD98059 did not inhibit prolactin-induced tyrosine phosphorylation of either Stat1, Stat3, or Stat5, despite effectively inhibiting MAPK activation.3 These experiments therefore did not suggest any causal link between MAPK inhibition and the selective inhibition of Stat1/3 tyrosine phosphorylation at high cell density but rather indicated that the two inhibitory events occur in parallel.

A final mechanistic matter relates to the observed lack of sensitivity of PRL-induced Jak2 tyrosine phosphorylation to kinase inhibitors. The specific resistance of Jak2 tyrosine phosphorylation to both staurosporine and genistein in Nb2 lymphocytes may suggest that Jak2 per se is not sensitive to these inhibitors. To our knowledge, the sensitivity of Jak2 to staurosporine or genistein has not been analyzed under stringent conditions in cell-free Jak2 kinase assays. The observation that staurosporine may inhibit cytokine-induced Jak2 tyrosine phosphorylation in some cellular models, e.g. growth hormone-induced Jak2 phosphorylation in fibroblasts (32), could reflect inhibition of one or more secondary tyrosine kinases that in certain cell lines contribute significantly to Jak2 tyrosine phosphorylation on multiple sites.

Context-sensitive Modulation of Discrete Signaling Pathways Downstream of PRL Receptors-- The extracelluar matrix is an important external modulator of cell fate (1) and is known to influence PRL signaling. Specifically, for PRL to activate Stat5 and induce lactogenic differentiation of mammary epithelial cells, a laminin-containing extracellular matrix was required that suppressed a prolactin receptor-associated protein tyrosine phosphatase (33, 34). The current observations on Nb2 lymphoma cells extends this phenomenon by describing a discriminative pattern of external regulation of individual signal transduction pathways downstream of PRL receptors. Provided that the observed changes in signaling repertoire have biological consequences for Nb2 cells, the modulated pathways may be viewed as sensors of the degree of cell crowding. The fact that significant quantitative changes occurred in some, but not all, PRL signals at different cell densities may also be directly linked to the associated growth inhibition. Although such a causal relationship remains to be proven, the observed suppression of MAPK activities may represent the most critical growth inhibitory component. Furthermore, the rapid uncoupling or heterologous desensitization of discrete PRL signals by an autocrine factor during cell crowding may reflect only one of many commonly operating mechanisms of external modulation of particular transduction pathways. Increased awareness of context-sensitive signaling pathways should also caution against simplistic interpretations of signaling data.

The observed resistance of Jak2 and Stat5 to inhibition at high cell density solidifies the Jak2-Stat5 axis as a distinct pathway as proposed by Groner and colleagues (35, 36). We have also recently shown that selective stimulation of Jak2 in Nb2 cells by the anti-apoptotic drug, aurintricarboxylic acid (ATA), exclusively led to activation of Stat5a and Stat5b, but not of Stat1 and Stat3 (26). Likewise, in this study, staurosporine treatment affected PRL-inducible activation of Stat1 and Stat3 but not Jak2 and Stat5. Therefore, accumulating evidence suggests that PRL activation of Jak2-Stat5 can be physiologically and pharmacologically dissociated from PRL activation of Stat1 and Stat3 in Nb2 cells. However, a clearer understanding of the biological roles of each of these pathways is needed to shed light on their involvement in disease progression and to establish a more specific pharmacological basis for their manipulation.

Characterization of the High Density Medium-associated Inhibitor-- Thus far, the majority of growth inhibitory factors isolated from cultured cells have been thermolabile polypeptides, including transforming growth factor-beta , interferons, glial maturation factor-beta , and mammastatin (for review, see Ref. 37). We have described the partial purification of a heat-stable low molecular weight inhibitory activity from conditioned high cell density culture medium. The activity was also resistant to extended treatment with the nonselective endoprotease, proteinase K. It is therefore possible that the factor is not a peptide. Proteinase K is active over a wide pH range, is insensitive to metal ions, and cleaves peptide bonds nonselectively after nonpolar or aromatic amino acids (28), which account for more than half of the natural amino acids. It will now be important to determine whether the endogenous inhibitor is indeed of nonpeptidyl nature, or whether it is a peptide without proteinase K-cleavable amide bonds. If the factor were not to be a peptide, membrane lipid derivatives such as prostaglandins or leukotrienes represent one candidate class of molecules, because eicosanoids can inhibit cell growth (38), are quickly released, and activate specific receptors (39). Further chemical analysis and purification of this factor is being pursued.

Relevance of the Endogenous Growth Inhibitor to Cancer Therapy-- Could identification of this soluble inhibitor from Nb2 lymphoma cells cultured at high density lead to new drugs against cancer? The success of antiproliferative interferons as adjuvant treatment for several types of malignancies has demonstrated the usefulness of natural growth inhibitors in cancer therapy (40). The observations that the endogenous inhibitor suppressed MAPK activities and may operate through a mechanism shared by staurosporine are encouraging. MAPKs are hyperactive in a large number of tumors (41), and at least two staurosporine analogues, 7-hydroxystaurosporine and N-benzoylstaurosporine, are currently in clinical trials for cancer treatment (42, 43). Because staurosporine inhibits a variety of protein kinases and induces apoptosis in many cell types (44, 45), more selective analogues may have fewer adverse effects and be less toxic. It will therefore also be important to establish to what extent the endogenous inhibitory activity described here will mimic all of the effects of staurosporine. A possible antiproliferative effect on cells of lymphoid origin would also be of direct relevance for pharmacologic immunosuppression.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant RO1 DK52013-01A1 and Uniformed Services University of the Health Sciences Grant RO74HF.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

parallel To whom correspondence should be addressed: Dept. of Pathology, Uniformed Services University of the Health Sciences School of Medicine, Bethesda, MD 20814. Tel.: 301-295-3801; Fax: 301-295-1640; E-mail hrui{at}usuhs.mil.

2 H. Yamashita, J. Xu, and H. Rui, unpublished data.

3 H. Yamashita and H. Rui, unpublished data.

    ABBREVIATIONS

The abbreviations used are: PRL, prolactin; MAPK, mitogenactivated protein kinase; HDM, high density medium; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PKC, protein kinase C.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Lin, C. Q., and Bissell, M. J. (1993) FASEB J. 7, 737-743[Abstract/Free Full Text]
  2. Juliano, R. (1996) Bioessays 18, 911-917[Medline] [Order article via Infotrieve]
  3. Fagotto, F., and Gumbiner, B. M. (1996) Dev. Biol. 180, 445-454[CrossRef][Medline] [Order article via Infotrieve]
  4. Fynan, T. M., and Reiss, M. (1993) Crit. Rev. Oncog. 4, 493-540[Medline] [Order article via Infotrieve]
  5. Harel, L., Chatelain, G., and Golde, A. (1984) J. Cell. Physiol. 119, 101-106[Medline] [Order article via Infotrieve]
  6. Couldwell, W. T., Yong, V. W., Dore-Duffy, P., Freedman, M. S., and Antel, J. P. (1992) J. Neurol. Sci. 110, 178-185[Medline] [Order article via Infotrieve]
  7. Gout, P. W., Beer, C. T., and Noble, R. L. (1980) Cancer Res. 40, 2433-2436[Abstract]
  8. Too, C. K., Murphy, P. R., and Friesen, H. G. (1989) Endocrinology 124, 2185-2192[Abstract]
  9. Yu-Lee, L. Y. (1997) Proc. Soc. Exp. Biol. Med. 215, 35-52[Abstract]
  10. Buckley, A. R., Rao, Y. P., Buckley, D. J., and Gout, P. W. (1994) Biochem. Biophys. Res. Commun. 204, 1158-1164[CrossRef][Medline] [Order article via Infotrieve]
  11. Ali, S., Pellegrini, I., and Kelly, P. A. (1991) J. Biol. Chem. 266, 20110-20117[Abstract/Free Full Text]
  12. Rui, H., Kirken, R. A., and Farrar, W. L. (1994) J. Biol. Chem. 269, 5364-5368[Abstract/Free Full Text]
  13. Rui, H., Lebrun, J. J., Kirken, R. A., Kelly, P. A., and Farrar, W. L. (1994) Endocrinology 134, 1289-1291
  14. Sidis, Y., and Horseman, N. D. (1994) Endocrinology 134, 1979-1985[Abstract]
  15. David, M., Petricoin, E. F., III, Igarashi, K., Feldman, G. M., Finbloom, D. S., and Larner, A. C. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7174-7178[Abstract]
  16. DaSilva, L., Rui, H., Erwin, R. A., Howard, O. M. Z., Kirken, R. A., Malabarba, M. G., Hackett, R. H., Larner, A. C., and Farrar, W. L. (1996) Mol. Cell. Endocrinol. 117, 131-140[CrossRef][Medline] [Order article via Infotrieve]
  17. Kirken, R. A., Malabarba, M. G., Xu, J., Liu, X., Farrar, W. L., Hennighausen, L., Larner, A. C., Grimley, P. M., and Rui, H. (1997) J. Biol. Chem. 272, 14098-14103[Abstract/Free Full Text]
  18. Clevenger, C. V., Torigoe, T., and Reed, J. C. (1994) J. Biol. Chem. 269, 5559-5565[Abstract/Free Full Text]
  19. Erwin, R. A., Kirken, R. A., Malabarba, M. G., Farrar, W. L., and Rui, H. (1995) Endocrinology 136, 3512-3518[Abstract]
  20. Rao, Y.-P., Buckley, D. J., and Buckley, A. R. (1995) Cell Growth Diff. 6, 1235-1244[Abstract]
  21. Clevenger, C. V., and Medaglia, M. V. (1994) Mol. Endocrinol. 8, 674-681[Abstract]
  22. Berlanga, J. J., Gualillo, O., Buteau, H., Applanat, M., Kelly, P. A., and Edery, M. (1997) J. Biol. Chem. 272, 2050-2052[Abstract/Free Full Text]
  23. Rao, Y.-P., Buckley, D. J., Olson, M. D., and Buckley, A. R. (1995) J. Cell. Physiol. 163, 266-276[Medline] [Order article via Infotrieve]
  24. Liu, X., Robinson, G. W., and Hennighausen, L. (1996) Mol. Endocrinol. 10, 1496-1506[Abstract]
  25. DaSilva, L., Howard, O. M. Z., Rui, H., Kirken, R. A., and Farrar, W. L. (1994) J. Biol. Chem. 269, 18267-18270[Abstract/Free Full Text]
  26. Rui, H., Xu, J., Mehta, S., Fang, H., Williams, J., Dong, F., and Grimley, P. M. (1998) J. Biol. Chem. 273, 28-32[Abstract/Free Full Text]
  27. Schaber, J. S., Fang, H., Xu, J., Grimley, P. M., and Rui, H. (1998) Cancer Res. 58, 1914-1919[Abstract]
  28. Forschung, B., and Darmstadt, E. M. (1974) Eur. J. Biochem. 47, 91-97[Medline] [Order article via Infotrieve]
  29. Yamashita, H., Xu, J., Erwin, R. A., Farrar, W. L., Kirken, R. A., and Rui, H. (1998) J. Biol. Chem. 273, 30218-30224[Abstract/Free Full Text]
  30. Carey, G. B., and Liberti, J. P. (1995) Arch. Biochem. Biophys. 316, 179-189[CrossRef][Medline] [Order article via Infotrieve]
  31. Tamaoki, T. (1991) Methods. Enzymol. 201, 340-347[Medline] [Order article via Infotrieve]
  32. Gong, T. W., Meyer, D. J., Liao, J., Hodge, C. L., Campbell, G. S., Wang, X., Billestrup, N., Carter-Su, C., and Schwartz, J. (1998) Endocrinology 139, 1863-1871[Abstract/Free Full Text]
  33. Streuli, C. H., Edwards, G. M., Delcommenne, M., Whitelaw, C. B., Burdon, T. G., Schindler, C., and Watson, C. J. (1995) J. Biol. Chem. 270, 21639-21644[Abstract/Free Full Text]
  34. Edwards, G. M., Wilford, F. H., Liu, X., Hennighausen, L., Djiane, J., and Streuli, C. H. (1998) J. Biol. Chem. 273, 9495-9500[Abstract/Free Full Text]
  35. Gouilleux, F., Wakao, H., Mundt, M., and Groner, B. (1994) EMBO J. 13, 4361-4369[Abstract]
  36. Barahmand-Pour, F., Meinke, A., Groner, B., and Decker, T. (1998) J. Biol. Chem. 273, 12567-12575[Abstract/Free Full Text]
  37. Johnson, T. C. (1994) Pharmacol. Ther. 62, 247-265[Medline] [Order article via Infotrieve]
  38. Marnett, L. J. (1992) Cancer Res. 52, 5575-5589[Medline] [Order article via Infotrieve]
  39. Smith, W. (1997) Adv. Exp. Med. Biol. 400B, 989-1011
  40. Einhorn, S., and Strander, H. (1993) Med. Oncol. Tumor Pharmacother. 10, 25-29[Medline] [Order article via Infotrieve]
  41. Sivaraman, V. S., Wang, H.-Y., Nuovo, G. J., and Malbon, C. C. (1997) J. Clin. Invest. 99, 1478-1483[Abstract/Free Full Text]
  42. Shao, R. G., Cao, C. X., Shimizu, T., O'Connor, P. M., Kohn, K. W., and Pommier, Y. (1997) Cancer Res. 57, 4029-4035[Abstract]
  43. van Gijn, R., van Tellingen, O., de Clippeleir, J. J., Hillebrand, M. J., Boven, E., Vermorken, J. B., ten Bokkel Huinink, W. W., Schwertz, S., Graf, P., and Beijnen, J. H. (1995) J. Chromatogr. B. Biomed. Appl. 667, 269-276[CrossRef][Medline] [Order article via Infotrieve]
  44. Ruegg, U. T., and Burgess, G. M. (1989) Trends. Pharmacol. Sci. 10, 218-220[CrossRef][Medline] [Order article via Infotrieve]
  45. Bertrand, R., Solary, E., O'Connor, P., Kohn, K. W., and Pommier, Y. (1994) Exp. Cell. Res. 211, 314-321[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.